Strides Pharma Science share news, announcements and annual reports
NSE: STARBSE: 532531Pharmaceuticals & BiotechnologySmall Cap
Strides Pharma Science Limited · Formerly Strides Shasun · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Feb 2000 on NSE, Jun 2004 on BSE
Last close ₹1,036.90down ₹31.90 (2.98%)BSE ₹1,037.80
Share price at the NSE close on 2 Nov 2026. Previous close ₹1,068.80.
2 Nov: open ₹1,067.30, high ₹1,067.30, low ₹1,013.90
52-week range of traded prices to 2 Nov 2026
₹768.65Low, 29 Jan 2026₹1,260.90High, 21 Sep 2026
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,557 Cr580th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 15.50
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.80
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 0.48%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 20.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 13.9%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.53
- Volume, NSEVolume. Shares traded on the last trading day. Volume in the glossary
- 4,07,986
Strides Pharma Science share news and announcements
1,447 announcements, routine notices left out, newest first. Page 27 of 29.
May 2009
5 May · Business
Press release titled "Strides Arcolab Commences commercial supplies of Oseltamivir Capsules For Influenza-A(H1N1) Virus (Swine Flu)". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements. For more details click here.
Apr 2009
24 Apr · Business
Press release dated April 24, 2009 titled "Financial Performance Q1-2009". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements For more details click here.24 Apr · Results
Standalone Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 16975.82 lacs for quarter ending on 31-MAR-2009 against Rs. 11968.8 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 2148.14 lacs for the quarter ending on 31-MAR-2009 against Rs. (1604.8) lacs for the quarter ending on 31-MAR-2008.24 Apr · Results
Consolidated Results for the quarter ended on 31-MAR-2009 as follows: Net Sales of Rs. 28425.77 lacs for quarter ending on 31-MAR-2009 against Rs. 20697.8 lacs for the quarter ending on 31-MAR-2008. Net Profit / (Loss) of Rs. 1048.18 lacs for the quarter ending on 31-MAR-2009 against Rs. 5259.4 lacs for the quarter ending on 31-MAR-2008.22 Apr · Meeting
Notice of the Extraordinary General Meeting of the Members of the Company will be held on May 13, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.15 Apr · Board meeting
Meeting on 24 Apr 2009: “Unaudited Financial Results for the qtr ended March 31, 2009”13 Apr · Issue of Warrants
The Board of Directors has approved issue of upto 6,200,000 warrants on a preferential basis to the Promoters/ Promoter Group / their Associates, subject to the Approval of the shareholders. The warrants will be convertible into equivalent number of equity shares of Rs. 10/- each and will be issued at a price not lower than the price specified in Chapter XIII of the SEBI (Disclosure and Investor Protection) Guidelines, 2000 and on such further terms and conditions specified in the said guidelines13 Apr · Business
Press release dated April 13, 2009, titled "Strides Arcolab to align its Global Operations into 3 Separate entities Specialty Pharmaceuticals, Pharmaceuticals & R&D". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.8 Apr · Board meeting
Inter-alia, consider various options of reorganizing the business of the Company and its Subsidiary Companies.8 Apr · Business
Press release dated April 08, 2009, titled "Strides Arcolab receives NDA approval from USFDA for Lamivudine and Stavudine under PEPFAR scheme Total PEPFAR approvals- 11". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Mar 2009
30 Mar · Meeting
Register of Members and Transfer Books of our Company will remain closed from April 18, 2009 to April 24, 2009 (both days inclusive), in connection with the Annual General Meeting of the Company convened to be held on April 24, 2009.27 Mar · Business
Press release dated March 27, 2009 titled "Strides Arcolab announces USFDA approval for one more product - Takes total sterile product approvals to 15 - First product approval for Strides Sagent JV." A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements. For more details click here.18 Mar · Business
Press release dated March 18, 2009 titled "Strides Receives USFDA Inspection Approval Status for its Steriles Injectable Complex 'Zero 483's Status'." . A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements. For more details click here.17 Mar · Disclosure
Remuneration Committee of the Company on March 17, 2009 has granted the following options: 1) 300,000 options under the Strides Arcolabs ESOP-2008 (Director) at Rs. 59.00 per option (exercise price) to a few eligible Directors of the Company. The shares covered by such options are 300,000 equity shares. 2) 100,000 options under the Strides Arcolab ESOP-2008 at Rs. 59.00 per option (exercise price) to an eligible employee of the company. The shares covered by such options are 100,000 equity shares.The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting.13 Mar · Updates
The 'License and Supply Agreement' signed by Strides Arcolab Limited with KV Pharmaceutical Company, USA (KV) in the year 2005, pursuant to which Strides had agreed to develop certain products to be exclusively licensed to KV and also manufacture and supply such products to KV for sale in certain territories. Due to the recent developments at KV Pharmaceutical Company, USA which included recall of their products, regulatory actions, filing of a series of class actions by shareholders etc., Strides has terminated the said 'License and Supply Agreement'.
Feb 2009
27 Feb · Management
Auditor's report in respect of the audited financial results for the quarter ended December 31,2008.A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Feb · Updates
Board of Directors has not recommended any dividend for the year ended December 31, 2008.26 Feb · Business
Press release dated February 25, 2009 with respect to the Audited financial results for the year ended December 31, 2008. A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements For more details click here.26 Feb · Miscellaneous
Details on Audited Accounts for the year ended December 31, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.26 Feb · Results
Consolidated Results for the year ended on 31-DEC-2008 as follows: Net Sales of Rs. 102033.1 lacs for year ending on 31-DEC-2008 against Rs. 72561.2 lacs for the year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 10796.38 lacs for the year ending on 31-DEC-2008 against Rs. (5012.1) lacs for the year ending on 31-DEC-2007.26 Feb · Results
Standalone Results for the year ended on 31-DEC-2008 as follows: Net Sales of Rs. 59313.75 lacs for year ending on 31-DEC-2008 against Rs. 39291.5 lacs for the year ending on 31-DEC-2007. Net Profit / (Loss) of Rs. 613.46 lacs for the year ending on 31-DEC-2008 against Rs. (11521.4) lacs for the year ending on 31-DEC-2007.16 Feb · Board meeting
To consider inter-alia, the audited financial results of the Company for the financial year ended December 31, 2008 and recommendation of dividend, if any.10 Feb · Disclosure
Disclosure of Pledged shares in terms of SEBI (Substantial Acquisition of Shares & Takeovers) (Amendment) Regulations, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jan 2009
15 Jan · Results
The Company will declare and publish the Audited Financial Results for the financial year ended December 31, 2008 before March 31, 2009. In view of the same, the Company would not be declaring and publishing the Unaudited Financial Results for the last quarter ended December 31, 2008 during the month of January 200913 Jan · Results
Based on the Scrutinizer's Report dated January 12, 2009, the special resolution seeking approval of the shareholders through Postal Ballot concerning the following matters have been carried out with requisite majority. (1) Approval to Strides Arcolab ESOP - 2008 (Director). (2) Extension of the Strides Arcolab ESOP - 2008 (Director) to the directors of company's subsidiaries5 Jan · Business
Press release dated January 05, 2009, titled "Balachandar to lead Human Resources at Strides". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Jan · Business
Press release dated January 02, 2009, titled "Strides Arcolab receives USFDA approval for two more products -Takes total Sterile product approvals to 14". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Dec 2008
15 Dec · Meeting
Pursuant to section 192A (2) of the Companies Act, 1956 read with Companies (Passing of the resolution by Postal Ballot) Rules, 2001, the Board of Directors of the Company has approved the following resolutions for approval of the Shareholders through Postal Ballot: 1) Special Resolution to accord approval to the Strides Arcolab - ESOP 2008 (Director) Scheme. 2) Special Resolution to accord approval to extending the Strides Arcolab - ESOP 2008 (Director) to the Directors of the Companies Subsidiaries (whether in India or abroad). The Company has appointed Mr. Gigi Joseph K.J., Practicing Company Secretary of M/s. SGB & Co., Company Secretaries, Bangalore as Scrutinizer for conducting the Postal Ballot process in a fair and transparent manner. The duly completed Postal Ballot forms should reach the Scrutinizer on or before the close of working hours on January 10, 2009. The Scrutinizer will submit his report after completion of the Scrutiny and the results of the Postal Ballot will be announced on January 12, 2009. A copy of the notice of Postal Ballot shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.3 Dec · Limited Review Report
Auditor's have conducted the limited review of the Un-Audited Financial Results for the quarter ended September 30, 2008. The details of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Nov 2008
24 Nov · Forfeiture of Warrants
This has reference to the 5,600,000 warrants issued by the Company on May 23, 2007 on preferential basis to M/s. Agnus Holdings Private Limited, a promoter group Company, entitling Agnus Holdings Private Limited to apply for an equivalent number of fully paid-up equity share of Rs. 10 each of the Company at any time during 18 months from the date of issue, at a price of Rs.342.10 per equity share. Subsequently, the company had allotted 50,000 shares to Agnus Holdings Private Limited on July 5, 2007 on their exercising the option to convert 50,000 warrants into equity shares. Please note that Agnus Holdings Private Limited has not exercised its right for conversion of the balance 5,550,000 warrants within the time stipulated under the preferential guidelines. Accordingly, the aforesaid 5,550,000 warrants now stands lapsed and the upfront money received against these warrants will be forfeited12 Nov · Management
Mr. Elcemar Almeida has resigned from the Board of Directors of the Company3 Nov · Business
Press release dated November 03, 2008, titled "Strides Arcolab receives USFDA approval for one more product - Takes total Sterile product approvals to 12". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Oct 2008
31 Oct · Disclosure
Board of Directors have approved the introduction of a new ESOP Scheme titled 'Strides Arcolab ESOP-2008 (Directors)' for issuance of upto 500,000 Options, subject to applicable statutory/ regulatory requirements.31 Oct · Business
Press release dated October 31, 2008, titled "Q3'08 Revenue up 32% to Rs. 282 Cr.; Operational EBITDA at Rs. 36.7 Cr. Up 128%; PAT at Rs. 105.40 Cr". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.31 Oct · Results
Standalone Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 16632.34 lacs for quarter ending on 30-SEP-2008 against Rs. 10586.4 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. (5167.61) lacs for the quarter ending on 30-SEP-2008 against Rs. 24.9 lacs for the quarter ending on 30-SEP-2007.31 Oct · Results
Consolidated Results for the quarter ended on 30-SEP-2008 as follows: Net Sales of Rs. 27210.33 lacs for quarter ending on 30-SEP-2008 against Rs. 20429.3 lacs for the quarter ending on 30-SEP-2007. Net Profit / (Loss) of Rs. 10534.9 lacs for the quarter ending on 30-SEP-2008 against Rs. (1190) lacs for the quarter ending on 30-SEP-2007.20 Oct · Board meeting
Meeting on 31 Oct 2008: “Unaudited financial results for qtr ended September 30, 2008”7 Oct · Business
Press release dated October 07, 2008, titled "Strides Arcolab Receives USFDA Approval For Its Oral Dosage Form Facility, Bangalore". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Sep 2008
16 Sep · Business
Press release dated September 16, 2008, titled "Strides Completes Business Rearrangement; Consolidates Steps to Profitable Growth". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Limited Review Report
Auditor's have conducted the limited review of the unaudited financial results for the quarter ended June 30, 2008. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.2 Sep · Business
Press release dated September 02, 2008, titled "Strides Arcolab receives USFDA approval for two more products - Takes total Sterile product approvals to 11". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements For more details click here.
Aug 2008
1 Aug · Business
Press release dated August 01, 2008, titled "Strides completes acquisition of controlling interest in Ascent Pharmahealth Limited (formely Genepharm Australasia Limited). Emerges as Australia's 4th largest Generic Company . Australasia becomes USD 90 Million operation for Strides". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.
Jul 2008
25 Jul · Grant of Options
Strides Arcolab Limited had informed the Exchange that : "The Remuneration Committee of the Company on July 22, 2008 has granted 7,15,000 options under the Strides Arcolab ESOP 2008 at Rs. 122.15/- per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 7,15,000 equity shares. The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting". The Company has now informed the Exchange regarding grant of options under Strides Arcolab ESOP 2008 Scheme wherein Company had inadvertently mentioned the number of options granted '715,000' instead of '665,000'.23 Jul · Business
Press release dated July 23, 2008, titled "Strides/Aspen Joint Venture; In-Licensing Deal with GSK". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.23 Jul · Grant of Options
The Remuneration Committee of the Company on July 22, 2008 has granted 7,15,000 options under the Strides Arcolab ESOP 2008 at Rs. 122.15/- per option (exercise price), to few Eligible Employees of the Company. The shares covered by such options are 7,15,000 equity shares. The vesting period of these options is in a phased manner over a period of three years. The options may be exercised within a period of 30 days from the date of vesting22 Jul · Results
Standalone Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 28046.21 lacs for half year ending on 30-JUN-2008 against Rs. 21129.3 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (7200.91) lacs for the half year ending on 30-JUN-2008 against Rs. 1794 lacs for the half year ending on 30-JUN-2007.22 Jul · Business
Press release dated July 22, 2008, titled "Q2'08 Revenue up - 49% to Rs. 269 Cr.; EBITDA at Rs. 55 Cr. - Up 176%; PAT Impacted by Exceptional items". A copy of the press release shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/Common/Corporate Announcements). For more details click here.22 Jul · Results
Consolidated Results for the half year ended on 30-JUN-2008 as follows: Net Sales of Rs. 46233.1 lacs for half year ending on 30-JUN-2008 against Rs. 34142.3 lacs for the half year ending on 30-JUN-2007. Net Profit / (Loss) of Rs. 375.09 lacs for the half year ending on 30-JUN-2008 against Rs. 1765.5 lacs for the half year ending on 30-JUN-2007.22 Jul · Results
Standalone Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 16077.45 lacs for quarter ending on 30-JUN-2008 against Rs. 10522.1 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (5596.11) lacs for the quarter ending on 30-JUN-2008 against Rs. 1018.1 lacs for the quarter ending on 30-JUN-2007.22 Jul · Results
Consolidated Results for the quarter ended on 30-JUN-2008 as follows: Net Sales of Rs. 25535.33 lacs for quarter ending on 30-JUN-2008 against Rs. 17989.9 lacs for the quarter ending on 30-JUN-2007. Net Profit / (Loss) of Rs. (4884.26) lacs for the quarter ending on 30-JUN-2008 against Rs. 1158.3 lacs for the quarter ending on 30-JUN-2007.